心血管研究技术2025:超越指南:DAPT选择和PCI前后持续时间
Kalyan R Chitturi1, Gregg W Stone2, Roxana Mehran2
1Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
概括
新的2025年指导方针对急性冠状动脉综合征 (ACS) 的皮肤冠状动脉干预 (PCI) 后的双重抗血小板治疗 (DAPT) 持续时间进行了改进. 专家们讨论了优化DAPT选择和持续时间,超出了针对个体患者需求的指南.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 临床指南 临床指南
背景情况:
- 双重抗血小板疗法 (DAPT) 对于急性冠状动脉综合征 (ACS) 的皮肤穿冠状动脉干预后 (PCI) 二次预防至关重要.
- 为了平衡缺血性保护与出血风险,需要仔细考虑DAPT持续时间.
- 主要心脏病学组织最近发布的2025年指导方针涉及ACS管理,包括DAPT策略.
研究的目的:
- 综合当前针对ACS的PCI后DAPT持续时间的指导方针指导建议.
- 介绍专家讨论关于在既定指南之外实施DAPT战略的讨论.
- 探索针对特殊人群的个性化降级和不断发展的治疗模式.
主要方法:
- 对2025年ACC/AHA/ACEP/NAEMSP/SCAI关于ACS管理的联合指南的审查.
- 来自2025年心血管研究技术 (CRT) 会议会议的专家见解的综合.
- 对临床场景的分析,以告知DAPT的选择和持续时间.
主要成果:
- 2025年指南强调了针对接受PCI的ACS患者DAPT持续时间的更新建议.
- 专家讨论强调需要个性化DAPT策略,超越标准建议.
- 考虑独特的临床情景和特殊人群是最佳DAPT管理的关键.
结论:
- 最佳的DAPT持续时间需要平衡有效性和安全性,以新的2025年建议为指导.
- 个性化降级策略和定制方法对于在不同患者群体中管理DAPT至关重要.
- 随着治疗环境的不断变化,需要对ACS进行PCI后的DAPT协议进行持续评估.
相关概念视频
01:27Coronary Artery Disease V: Interprofessional Care
37
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
37
01:27Peripheral Artery Disease III: Interprofessional Care
30
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
30
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
651
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
651
01:26Angina IV: Management
27
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
27
01:28Acute Coronary Syndrome IV: Interprofessional Care
32
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
01:26Atherosclerosis III: Management
40
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
40